Clinical trial · Observational
Establishment and Characterization of Meningioma Patient-derived Organoids
NCT04478877CI-TRIAL-00069369completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, meningioma organoids will be established from patients' tissues and the characterization of the organoid will be performed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Meningioma | Meningioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Whole exome sequencing data
- timeFrame
- 7 days
- description
- DNA extracted from patient tumor tissue and patients-derived organoids will be perform whole exome sequencing for genetic characterization.
Secondary outcomes (1)
- measure
- Immunostaining
- timeFrame
- 7 days
- description
- H\&E staining and meningioma markers immunostaining
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult patients (aged \>18 years) with meningioma 2. Admission into Prince Wales hospitals neurosurgical services 3. Patients with surgical needs of meningioma removal Exclusion Criteria: 1\. Patients (or next-of-kin as appropriate) refuse to participate into the study
References
Publications (0)
Data not yet available
No reference posted for this study.